Androgen deprivation therapy (ADT) is still a mainstay of treatment for advanced prostate cancer. Continuous ADT causes considerable patient morbidity including sexual dysfunction, poor mood and physical capacity, changes in body composition and health-care-related costs. Intermittent ADT has been used as an approach to ADT monotherapy to limit morbidity by enabling cyclical recovery of serum testosterone levels. To date, a number of well-performed randomized controlled trials and meta-analyses have demonstrated statistically insignificant differences in oncological outcomes between intermittent and continuous ADT monotherapy. Sexual outcomes, morbidity profiles and cost-savings favour intermittent therapy in most randomized trials, but the benefit for clinical practice is unclear. Despite the growing body of evidence, the optimal administration regime for ADT has not been clearly established and incorporation of adjunctive upfront treatments such as chemotherapy and novel anti-androgen agents has further hampered progress. Recommendations by authoritative urological and oncological societies regarding the use of intermittent ADT are limited. The potential benefits of reduced morbidity for a particular patient must be considered in light of the possible oncological outcomes. Although the oncological changes associated with intermittent ADT are controversial, intermittent ADT does seem to provide symptomatic benefit in patients compared with continuous ADT. However, careful selection of suitable patients is crucial.
Intermittent androgen deprivation therapy (ADT) has been proposed to reduce the adverse events and poor quality of life associated with continuous ADT.
Current data do not show that intermittent ADT is inferior to continuous ADT with statistical certainty.
Quality-of-life measures (including mental health, physical capacity and sexual health) favour intermittent ADT compared with continuous ADT.
In the current era of early systemic therapy for hormone-sensitive disease, intermittent ADT is likely to be best suited to patients with M0 or low-volume M1 disease.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Journal of Human Genetics Open Access 13 May 2021
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 66, 7–30 (2016).
Bartsch, G. et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 58, 417–424 (2001).
Stamey, T. A. et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J. Urol. 172, 1297–1301 (2004).
Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737–746 (2015).
Huggins, C. & Hodges, C. V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J. Urol. 168, 9–12 (2002).
Recine, F. & Sternberg, C. N. Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer. Transl Androl. Urol. 4, 355–364 (2015).
Cornford, P. et al. EAU-ESTRO-SIOG guidelines on prostate cancer. II. Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur. Urol. 71, 630–642 (2017).
Wong, Y. N. et al. Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat. Rev. Clin. Oncol. 11, 365–376 (2014).
Lilja, H., Ulmert, D. & Vickers, H. J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer 8, 268–278 (2008).
James, N. D., Spears, M. R. & Sydes, M. R. Abiraterone in metastatic prostate cancer. N. Engl. J. Med. 377, 1696–1697 (2017).
Thomsen, F. B. et al. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study. Eur. J. Cancer 51, 1283–1292 (2015).
Studer, U. E. et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J. Clin. Oncol. 24, 1868–1876 (2006).
Graff, J. N. & Beer, T. M. Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents. Drugs Aging 31, 873–882 (2014).
Dragomir, A. et al. Treatment patterns and trends in patients dying of prostate cancer in Quebec: a population-based study. Curr. Oncol. 24, 240–248 (2017).
Muralidhar, V. et al. Duration of androgen deprivation therapy for high-risk prostate cancer: application of randomized trial data in a tertiary referral cancer center. Clin. Genitourin. Cancer 14, e299–e305 (2015).
Sammon, J. D. et al. Patterns of declining use and the adverse effect of primary androgen deprivation on all-cause mortality in elderly men with prostate cancer. Eur. Urol. 68, 32–39 (2015).
Ziehr, D. R. et al. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int. 116, 358–365 (2015).
Higano, C. S. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 61, 32–38 (2003).
Gleave, M. et al. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Prostate Cancer Prostatic Dis. 1, 289–296 (1998).
Klotz, L. H. et al. Intermittent endocrine therapy for advanced prostate cancer. Cancer 58, 2546–2550 (1986).
Bruchovsky, N. et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 50, 2275–2282 (1990).
Goldenberg, S. L. et al. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45, 839–844 (1995).
Shaw, G. L. et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int. 99, 1056–1065 (2007).
Magnan, S. et al. Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. JAMA Oncol. 1, 1261–1269 (2015).
Niraula, S., Le, L. W. & Tannock, I. F. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J. Clin. Oncol. 31, 2029–2036 (2013).
Botrel, T. E. et al. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis. BMC Urol. 14, 9 (2014).
Sciarra, A. & Salciccia, S. A novel therapeutic option for castration-resistant prostate cancer: after or before chemotherapy? Eur. Urol. 65, 905–906 (2014).
Tsai, H. T. et al. Adoption of intermittent androgen deprivation therapy for advanced prostate cancer: a population based study in American urology practice. Urol. Pract. 2, 190–198 (2015).
Liede, A. et al. International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries. ESMO Open 1, e000040 (2016).
de Leval, J. et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin. Prostate Cancer 1, 163–171 (2002).
Irani, J. et al. Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study. Eur. Urol. 54, 382–391 (2008).
Salonen, A. J. et al. Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects. Eur. Urol. 63, 111–120 (2013).
Salonen, A. J. et al. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. J. Urol. 187, 2074–2081 (2012).
Hussain, M. et al. Intermittent versus continuous androgen deprivation in prostate cancer. N. Engl. J. Med. 368, 1314–1325 (2013).
Yamanaka, H. et al. Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer. Prostate 63, 56–64 (2005).
Calais da Silva, F. et al. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group. Eur. Urol. 66, 232–239 (2014).
Schasfoort, E., et al. Intermittent androgen suppression with buserelin and nilutamide for the treatment of prostate cancer patients. Eur. Urol. Suppl. 2, 187 (2003).
Mottet, N. et al. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial. BJU Int. 110, 1262–1269 (2012).
Tunn, U. et al. Intermittent androgen deprivation in patients with PSA-Relapse after radical prostatectomy: final results of a European randomized prospective phase-III clinical trial AUO study AP 06/95, EC 507. J. Urol. 177, 201 (2007).
Hering, F. et al. Metastatic adenocarcinoma of the prostate: comparison between continuous and intermittent hormonal treatment. Braz. J. Urol. 26, 276–282 (2000).
Verhagen, P. C. et al. Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial. World J. Urol. 32, 1287–1294 (2014).
Shim, M. et al. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: goserelin versus triptorelin versus leuprolide. Investig. Clin. Urol. 60, 244–250 (2019).
Calais da Silva, F. E. et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur. Urol. 55, 1269–1277 (2009).
Crook, J. M. et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N. Engl. J. Med. 367, 895–903 (2012).
Miller, K., Steiner, U. & Lingnau, A. Intermittent vs continuous androgen suppression in advanced prostate cancer: a randomised prospective study. J. Urol. 177, 573 (2007).
Hussain, M. et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J. Clin. Oncol. 24, 3984–3990 (2006).
Arai, Y., Yoshiki, T. & O. Yoshida, O. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. J. Urol. 144, 1415–1419 (1990).
Tombal, B. et al. Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol. 15, 592–600 (2014).
Klotz, L. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 102, 1531–1538 (2008).
Scher, H. I. et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J. Clin. Oncol. 22, 537–556 (2004).
Duchesne, G. M. et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 17, 727–737 (2016).
Evens, A. M., Lestingi, T. M. & Bitran, J. D. Intermittent androgen suppression as a treatment for prostate cancer: a review. Oncologist 3, 419–423 (1998).
Abrahamsson, P. A. Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots. Asian J. Urol. 4, 208–222 (2017).
Schulman, C. et al. Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: a phase 3b randomised study (ICELAND). Eur. Urol. 69, 720–727 (2016).
Brungs, D. et al. Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 17, 105–111 (2014).
Hussain, M. et al. Evaluating intermittent androgen-deprivation therapy phase III clinical trials: the devil is in the details. J. Clin. Oncol. 34, 280–285 (2016).
Hershman, D. L. et al. Adverse Health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol. 2, 453–461 (2016).
Bruchovsky, N. et al. Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. Clin. Genitourin. Cancer 6, 46–52 (2008).
Jin, C. et al. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients. Prostate Cancer Prostatic Dis. 19, 429 (2016).
McDuff, S. G. R. et al. Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer. Cancer 124, 1391–1399 (2018).
Cano, A. & Baal, W. M. Van The mechanisms of thrombotic risk induced by hormone replacement therapy. Maturitas 40, 17–38 (2001).
Li, S. et al. Experimental arterial thrombosis regulated by androgen and its receptor via modulation of platelet activation. Thromb. Res. 121, 127–134 (2007).
O’Farrell, S. et al. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J. Clin. Oncol. 33, 1243–1251 (2015).
Damber, J. E. et al. The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients. Urology 80, 174–180 (2012).
Corona, G. et al. Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS). J. Sex. Med. 7, 1362–1380 (2010).
Nguyen, P. L. et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur. Urol. 67, 825–836 (2015).
Corona, G. et al. Androgen deprivation therapy in prostate cancer: focusing on sexual side effects. J. Sex. Med. 9, 887–902 (2012).
Potosky, A. L. et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J. Clin. Oncol. 19, 3750–3757 (2001).
Fowler, F. J. Jr. et al. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer 95, 287–295 (2002).
Watkins Bruner, D. et al. Randomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: results of RTOG 0215. J. Sex. Med. 8, 1228–1238 (2011).
Salonen, A. J. et al. Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII. Scand. J. Urol. 48, 513–522 (2014).
Boccon-Gibod, L. et al. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer. Eur. Urol. 66, 655–663 (2014).
Cleary, P. D., G. Morrissey, G. & Oster, G. Health-related quality of life in patients with advanced prostate cancer: a multinational perspective. Qual. Life Res. 4, 207–220 (1995).
Mondaini, N. et al. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? J. Sex. Med. 4, 1708–1712 (2007).
Wittmann, D. et al. The psychosocial aspects of sexual recovery after prostate cancer treatment. Int. J. Impot. Res. 21, 99–106 (2009).
Nelson, C. J. et al. Determinants of sexual satisfaction in men with prostate cancer. J. Sex. Med. 4, 1422–1427 (2007).
Organ, M. et al. Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa): results of a multi-institutional randomized prospective clinical trial. Am. J. Clin. Oncol. 36, 601–605 (2013).
Fayers, P. et al. Quality of life research within the EORTC — the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur. J. Cancer 38 (Suppl. 4), 125–133 (2002).
Koga, H., Naito, S. & Ito, K. Quality of life in locally advanced prostate cancer patients who underwent hormonal treatment combined with radiotherapy. Nishi Nihon Hinyokika 66, 255–262 (2004).
Nead, K. T. et al. Association of androgen deprivation therapy and depression in the treatment of prostate cancer: a systematic review and meta-analysis. Urol. Oncol. 35, 664 e1–664 e9 (2017).
Nead, K. T., Sinha, S. & Nguyen, P. L. Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 20, 259–264 (2017).
Bonfill, X. et al. Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach. Cancer Manag. Res. 10, 2357–2367 (2018).
Eknoyan, D., Hurley, R. A. & Taber, K. H. The neurobiology of placebo and nocebo: how expectations influence treatment outcomes. J. Neuropsychiatry Clin. Neurosci. 25, vi–254 (2013).
Fizazi, K. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377, 352–360 (2017).
Kyriakopoulos, C. E. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 chaarted trial. J. Clin. Oncol. 36, 1080–1087 (2018).
Cattrini, C. et al. Current treatment options for metastatic hormone-sensitive prostate cancer. Cancers 11, 1355 (2019).
Boeve, L. M. S. et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur. Urol. 75, 410–418 (2019).
Parker, C. C. et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392, 2353–2366 (2018).
Sooriakumaran, P. Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomized controlled feasibility trial. BJU Int. 120, E8–E20 (2017).
Clarke, N. W. et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann. Oncol. 30, 1992–2003 (2019).
Bitting, R. L., et al. Phase II trial of enzalutamide and androgen deprivation therapy with salvage radiation in men with high-risk prostate-specific antigen recurrent prostate cancer: the STREAM trial. Eur. Urol. Oncol. https://doi.org/10.1016/j.euo.2020.01.005 (2020).
Klotz, L. & Higano, C. S. Intermittent androgen deprivation therapy-an important treatment option for prostate cancer. JAMA Oncol. 2, 1531–1532 (2016).
Mohler, J. L. et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 17, 479–505 (2019).
National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management. NICE https://www.nice.org.uk/guidance/ng131/resources/prostate-cancer-diagnosis-and-management-pdf-66141714312133 (2019).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03630666 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03689699 (2019).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03511196 (2020).
Langenhuijsen, J. F. et al. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer. Urol. Oncol. 31, 549–556 (2013).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03007732 (2020).
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Perera, M., Roberts, M.J., Klotz, L. et al. Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer. Nat Rev Urol 17, 469–481 (2020). https://doi.org/10.1038/s41585-020-0335-7
This article is cited by
Journal of Human Genetics (2021)